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Gastric cancer is a peritoneal-borne disease. Although
our attention usually first turns to regional lymphatic
extension in cases of localized disease, we know that most
gastric adenocarcinomas will eventually spread to the
peritoneum sooner or later in their natural history, even in
the absence of lymph node involvement. Moreover, peri-
toneal carcinomatosis is a common manifestation of
recurrent disease after curative-intent resection, even when
the most efficacious adjuvant or neoadjuvant treatments
have been used. The adverse prognostic effect of peritoneal
dissemination in this disease is well acknowledged, no
matter whether it consists of established macroscopic
implants or isolated free cancer cells (detected by perito-
neal washing cytology) with no overt peritoneal
carcinomatosis. In both cases, current treatment guidelines
call for palliative therapeutic measures based on systemic
chemotherapy.
Much progress has occurred in recent years in the
adjuvant and neoadjuvant treatment of locally advanced
gastric cancer, leading to changes in practice across the
United States and Europe. Promising reports on the man-
agement of peritoneal carcinomatosis from gastric cancer
have also been produced, both by Yonemura et al. in Japan
and Glehen et al. in France, although these have not
attracted as much attention.1,2 The authors of these studies
concur that a complete resection of all visible disease
(primary tumor and peritoneal implants), combined with
hyperthermic intraperitoneal chemotherapy (HIPEC), offer
a chance for long-term survival in this adverse scenario.
Although these are neither randomized nor large-size trials,
they call our attention to the fact that progress in the
management of peritoneal carcinomatosis from gastric
cancer is likewise possible and worth exploring.
Okabe and colleagues have pursued this task as well.
Their study in the present issue of Annals of Surgical
Oncology adds to the expectations created by the afore-
mentioned phase II efforts.3 The strategy evaluated by
Okabe et al. consists of radical surgery for the primary
tumor after adequate response of the peritoneal disease to
two cycles of systemic chemotherapy with S-1 and cisplatin
(a common regimen for disseminated gastric cancer in
Japan), as assessed at surgical exploration. Those patients
with a complete peritoneal response (overall 46%) showed a
survival advantage over those who did not respond.
Resection of residual peritoneal disease (if present) or of
posttreatment peritoneal scarring was not pursued. They
report an impressive 43-month median survival in the group
of patients who underwent an R0 resection, as well as a
small but real number of patients who remained free of
disease after 4 years. Although this is a small retrospective
study of 41 patients with various degrees of peritoneal
involvement, the bottom line is that a subset of patients with
peritoneal spread—macroscopic, microscopic, or both—
who are candidates only for palliative chemotherapy by
present standards, may become long-term survivors when
treated by a curative-intent approach that combines induc-
tion systemic chemotherapy and radical surgery. The data
of the Okabe study add to that of the Yonemura and Glehen
studies in underlining two important facts: a complete sur-
gical clearance of all macroscopic disease is an absolute
requirement for improved survival, and the more limited the
peritoneal disease volume and extension, the more likely it
is that this goal may be achieved.
The strategy of using induction chemotherapy in prep-
aration for radical resection in gastric cancer with
peritoneal seeding has already been reported by Yonemura
et al. and is a recognized line of clinical research in this
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field.4 Yonemura and colleagues use iterative cycles of
neoadjuvant concurrent intraperitoneal and systemic che-
motherapy (the so-called NIPS approach) with the aim of
chemically cytoreducing the macroscopic peritoneal dis-
ease and eliminating the microscopic free cancer cell
component, thus maximizing the chances of achieving a
complete cytoreduction. A negative peritoneal cytology is
an absolute requirement to submit these patients for cyto-
reductive surgery and HIPEC, according to the work of
Yonemura and colleagues. The unfavorable prognostic
effect of a positive peritoneal cytology, regardless of the
presence or absence of peritoneal implants (p status), is
again stressed in the study of Okabe and colleagues by the
dramatic difference in response to the induction chemo-
therapy between cytology-negative (82%) and cytology-
positive cases (37%), and ultimately in survival. The
message seems clear that free cancer cells in the peritoneal
cavity, if present, need to be specifically targeted in order
to make a difference in the outcome of gastric cancer
patients with peritoneal spread.
From a surgical oncologist perspective, dealing with
patients with peritoneal seeding from gastric cancer is
difficult, demanding, and often unrewarding. However,
these patients are not scarce in our practices. Peritoneal
dissemination from gastric cancer can be treated, and better
outcomes than those provided by systemic chemotherapy
alone are possible in selected patients. Our enemies are
invisible free cancer cells as much as widespread macro-
scopic implants. Our tools include radical surgery and a
chemotherapeutic targeting of the peritoneal surfaces
without neglecting systemic disease control. Studies like
that of Okabe and colleagues, even if retrospective and
small in size, have their value as they join others in the
exploration of new strategies that can provide the glimmer
of hope sought by Sugarbaker and Yonemura in the man-
agement of this difficult disease.5 They provide the bases
upon which larger prospective trials can be designed. There
are many questions to be answered, the most important
being how to identify that subset of patients who will
benefit most from a radical treatment approach. Following
this line, a multicentric prospective phase II trial exploring
the combination of NIPS followed by cytoreductive sur-
gery and HIPEC plus subsequent systemic chemotherapy is
being conducted by the Spanish Peritoneal Surgical
Oncology Group (GECOP), with the aim of making further
progress in the management of peritoneal seeding from
gastric cancer.
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